Life Technologies and the Structural Genomic Consortium (SGC) are partnering with antibody technology experts at the Universities of Chicago, and Toronto, to generate what they say will be the first-ever master set of high-quality epigenetic-targeting recombinant antibodies for use in disease-related research. The first 58 of 200 antibodies in development are already being made available to the scientific community.
The partners claim the antibody set will provide a new standard, to enable more effective study of the epigenetic regulatory proteins in a wide range of disease fields. “The partnership is prepared to produce a set of 200 highly specific, highly sensitive antibodies that are validated for specific applications,” comments Aled Edwards, Ph.D., CEO and director of SGC. “These 58 now being launched are the first step toward developing the de facto standard set of quality epigenetics antibodies that researchers can use for generations to come.”
SGC is a nonprofit organization involving 200 researchers at the University of Toronto, and University of Oxford (U.K.), together with six pharmaceutical companies: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and Takeda.
